Objective This paper is a systematic review on seizures under treatment with substances
licensed for major depression. Method Systematic review protocol is available in …

We tried to review and update clinical and preclinical studies evaluating vilazodone's role as
an antidepressant for patients with major depressive disorder (MDD). In terms of its …

Forensic professionals, particularly medical examiners—often working through heavy
caseloads—require quick and easy access to reliable sources of information to help …

Background: Vilazodone is an antidepressant with selective serotonin reuptake inhibition
and partial 5HT1A agonism. Serotonin syndrome is believed to be due to excessive …

Background Vilazodone is a selective serotonin reuptake inhibitor and 5HT 1A agonist
recently approved to treat depression in adults. To date, there are minimal data available …

Antidepressant adverse effects continue to receive attention in large-scale population
studies. These reports have demonstrated an increased risk of venous thromboembolism …

Vilazodone is a new selective serotonin reuptake inhibitor (SSRI) and serotonin 5‐HT 1a
partial agonist that is approved by the U nited S tates F ood and D rug A dministration to treat …

Background Vilazodone was approved by the US Food and Drug Administration in 2011 as
a treatment for major depression disorder. Vilazodone is a selective serotonin reuptake …

Vilazodone hydrochloride is the first member in a new class of antidepressants called
indolealkylamines and was approved for use in the United States in 2011 for major …

Background: Unintentional ingestion of selective serotonin reuptake inhibitor (SSRI)
medications is common amongst children< 6 years of age. Current evidence-based …